Criterium, Inc.
Quick facts
Phase 3 pipeline
- AMG 510 · Oncology
AMG 510 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Criterium, Inc.
What is Criterium, Inc.'s pipeline?
Criterium, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include AMG 510.
Related
- Sector hub: All tracked pharma companies